Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEMEYA vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective inhibitor of Janus kinase 1 (JAK1), modulating the JAK-STAT signaling pathway to reduce pro-inflammatory cytokine production.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
FDA-approved: Treatment of moderate to severe rheumatoid arthritis in adult patients with an inadequate response to methotrexate.,Off-label: Not typically used off-label due to limited data.
Prevention of pregnancy
KEMEYA (zoledronic acid) 5 mg intravenously once yearly for osteoporosis. For Paget disease, 5 mg intravenously as a single dose.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life: 12-15 hours; Clinical context: allows twice-daily dosing; prolonged in renal impairment (up to 24-30 hours in Cr Cl <30 m L/min)
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19. Forms inactive metabolites.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: ~70% as unchanged drug; Fecal: ~20% as metabolites; Biliary: <10%
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
High: ~95% bound to albumin and alpha-1-acid glycoprotein
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Vd: 3-5 L/kg; indicates extensive tissue distribution
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 80-90%
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
Contraindicated if Cr Cl <35 m L/min; for osteoporosis, not recommended if Cr Cl <35 m L/min. No dose adjustment needed for Cr Cl >=35 m L/min.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
No specific dose adjustment required for hepatic impairment; caution in severe hepatic impairment due to limited data.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy not established in children; no approved pediatric dosing.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific dose adjustment for elderly; monitor renal function as age-related decline in Cr Cl may necessitate avoidance if Cr Cl <35 m L/min.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, AND THROMBOSIS. Patients treated with KEMEYA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants. If a serious infection develops, interrupt KEMEYA until the infection is controlled. Reported infections include active tuberculosis, invasive fungal infections, and infections due to opportunistic pathogens. Malignancies, including lymphoma, have been observed. Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have been reported. Consider risks vs benefits before initiating therapy.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Risk of serious infections, including tuberculosis and invasive fungal infections.,Avoid use in patients with active infections.,Monitor for signs and symptoms of infection during treatment.,Risk of thrombosis: Use with caution in patients with risk factors for thrombosis.,Risk of malignancy, particularly lymphoma.,Hepatotoxicity: Monitor liver enzymes regularly.,Cytopenias: Monitor complete blood counts at baseline and periodically.,Gastrointestinal perforations have been reported; monitor for abdominal pain.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Hypersensitivity to the active substance or any excipients.,Active serious infections, including localized infections.,Known active tuberculosis.,Severe hepatic impairment (Child-Pugh C).,Pregnancy (based on animal studies showing fetal harm).
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific food restrictions. Grapefruit product interactions are not clinically significant. Avoid estrogen-containing foods (e.g., soy supplements) as they may reduce efficacy.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
KEMEYA is contraindicated in pregnancy. Based on animal studies and its mechanism of action, KEMEYA may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Teratogenic effects have been observed in animal reproduction studies at doses below the recommended human dose. In particular, exposure during the first trimester is associated with major congenital malformations, including neural tube defects, craniofacial abnormalities, and cardiovascular defects. During the second and third trimesters, fetal growth restriction and oligohydramnios may occur.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
It is not known whether KEMEYA is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from KEMEYA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. The milk-to-plasma (M/P) ratio has not been determined for KEMEYA.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Due to the risk of fetal harm, KEMEYA is contraindicated in pregnancy, and no dose adjustments are recommended. If inadvertent exposure occurs during pregnancy, the drug should be discontinued immediately. The pharmacokinetics of KEMEYA in pregnant women have not been studied, and thus no specific dosing guidelines for pregnancy exist.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
KEMEYA (letrozole) is an aromatase inhibitor used for hormone receptor-positive breast cancer. Monitor for bone mineral density loss and consider bisphosphonates. Not effective in estrogen receptor-negative tumors. Avoid in premenopausal women without concurrent ovarian suppression. Dose adjustment needed in severe hepatic impairment (Child-Pugh C).
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take exactly as prescribed, usually once daily without regard to meals.,Report any new bone pain, joint stiffness, or fractures promptly.,Use effective non-hormonal contraception if premenopausal; letrozole can cause fetal harm.,May cause hot flashes, fatigue, and night sweats; these are not dangerous.,Do not take estrogen-containing medications or supplements while on letrozole.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEMEYA vs ALYACEN 1/35, answered by our medical review team.
KEMEYA is a Oral Contraceptive that works by Selective inhibitor of Janus kinase 1 (JAK1), modulating the JAK-STAT signaling pathway to reduce pro-inflammatory cytokine production.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEMEYA and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEMEYA is: KEMEYA (zoledronic acid) 5 mg intravenously once yearly for osteoporosis. For Paget disease, 5 mg intravenously as a single dose.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEMEYA and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEMEYA is classified as Category C. KEMEYA is contraindicated in pregnancy. Based on animal studies and its mechanism of action, KEMEYA may cause fetal harm when administered to a pregnant woman. There are no adequat. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.